# US 2021/0069141 A1 · Anti-inflammatory agent containing rare fatty acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069141 A1
- Document ID: US20210069141A1
- Status: Published application
- Kind: A1
- Application number: 16/953,129
- Filed: 2020-11-19
- Published: 2021-03-11
- Earliest claimed: 2014-01-24
- Assignees: Kyoto University; Nitto Pharmaceutical Industries, Ltd.
- Applicants: Kyoto University; Nitto Pharmaceutical Industries, Ltd.
- Inventors: Jun OGAWA; Shigenobu KISHINO; Teruo KAWADA; Nobuyuki TAKAHASHI; Tsuyoshi GOTO; Tatsuya SUGAWARA; Yasunori YONEJIMA
- Web page: https://patentgrep.com/patent/US20210069141A1

## CPC

- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A23L 33/12: Fatty acids or derivatives thereof
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an anti-inflammatory agent containing a rare fatty acid such as hydroxylated fatty acid, oxo fatty acid and the like, and further, food, pharmaceutical product and the like containing the anti-inflammatory agent.

## Claims

### Claim 1

A method for the prophylaxis or treatment of an inflammatory disease, comprising administering to a patient an effective amount of a fatty acid that is
(1) a fatty acid having 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position,
(2) a fatty acid having 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position,
(3) a fatty acid having 18 or 20 carbon atoms and a hydroxyl group or carbonyl group at the 12-position,
(4) a fatty acid having 20 carbon atoms and a hydroxyl group or carbonyl group at the 15-position, or
(5) a fatty acid having 16 carbon atoms and a hydroxyl group or carbonyl group at the 10-position.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the inflammatory disease is an inflammatory disease involving macrophage.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the fatty acid is
(1) a saturated fatty acid or an unsaturated fatty acid having a trans double bond at the 11-position or at least one cis double bond at the 6-position, the 12-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position,
(2) a saturated fatty acid or an unsaturated fatty acid having at least one cis double bond at the 6-position, the 9-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position,
(3) a saturated fatty acid or an unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 9-position, the 14-position, the 17-position, which has 18 or 20 carbon atoms and a hydroxyl group or carbonyl group at the 12-position,
(4) an unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 11-position, the 17-position, which has 20 carbon atoms and a hydroxyl group or carbonyl group at the 15-position, or
(5) a saturated fatty acid having 16 carbon atoms and a hydroxyl group or carbonyl group at the 10-position.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the fatty acid is
(1) a saturated fatty acid or an unsaturated fatty acid having a trans double bond at the 11-position or at least one cis double bond at the 6-position, the 12-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position,
(2) a saturated fatty acid or an unsaturated fatty acid having at least one cis double bond at the 6-position, the 9-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position, or
(3) saturated fatty acid having 18 carbon atoms and a hydroxyl group at the 12-position.

### Claim 5 (depends on 3)

The method according to claim 3, wherein
(1) the saturated fatty acid or the unsaturated fatty acid having a trans double bond at the 11-position or at least one cis double bond at the 6-position, the 12-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position, is 10-hydroxy-cis-12-octadecenoic acid, 10-hydroxy-cis-12,cis-15-octadecadienoic acid, 10-hydroxy-cis-6,cis-12-octadecadienoic acid, 10-hydroxy-cis-6,cis-12,cis-15-octadecatrienoic acid, 10,12-dihydroxy-octadecanoic acid, 10-hydroxy-octadecanoic acid, 10-hydroxy-cis-15-octadecenoic acid, 10-hydroxy-cis-6-octadecenoic acid, 10-hydroxy-cis-6,cis-15-octadecadienoic acid, 10-hydroxy-trans-11-octadecenoic acid, 10-hydroxy-trans-11,cis-15-octadecadienoic acid, 10-hydroxy-cis-6,trans-11-octadecadienoic acid, 10-hydroxy-cis-6,trans-11,cis-15-octadecatrienoic acid, 10-oxo-cis-12-octadecenoic acid, 10-oxo-cis-12,cis-15-octadecadienoic acid, 10-oxo-cis-6,cis-12-octadecadienoic acid, 10-oxo-cis-6,cis-12,cis-15-octadecatrienoic acid, 10-oxo-octadecanoic acid, 10-oxo-cis-6-octadecenoic acid, 10-oxo-cis-15-octadecenoic acid, 10-oxo-cis-6,cis-15-octadecadienoic acid, 10-oxo-trans-11-octadecenoic acid, 10-oxo-cis-6, trans-11-octadecadienoic acid, 10-oxo-trans-11,cis-15-octadecadienoic acid, or 10-oxo-cis-6,trans-11,cis-15-octadecatrienoic acid,
(2) the saturated fatty acid or the unsaturated fatty acid having at least one cis double bond at the 6-position, the 9-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position, is 13-hydroxy-cis-9-octadecenoic acid, 13-hydroxy-cis-6,cis-9-octadecadienoic acid, 13-hydroxy-cis-9,cis-15-octadecadienoic acid, 13-hydroxy-cis-6,cis-9,cis-15-octadecatrienoic acid, 10,13-dihydroxy-octadecanoic acid, 10,13-dihydroxy-cis-6-octadecenoic acid, 10,13-dihydroxy-cis-15-octadecenoic acid, 10,13-dihydroxy-cis-6,cis-15-octadecadienoic acid, 10-oxo-13-hydroxy-octadecanoic acid, 10-oxo-13-hydroxy-cis-6-octadecenoic acid, 10-oxo-13-hydroxy-cis-15-octadecenoic acid, 10-oxo-13-hydroxy-cis-6,cis-15-octadecadienoic acid, 13-hydroxy-cis-5,cis-9-octadecadienoic acid, 13-hydroxy-trans-5,cis-9-octadecadienoic acid, 13-oxo-cis-9-octadecenoic acid, 13-oxo-cis-6,cis-9-octadecadienoic acid, 13-oxo-cis-9, cis-15-octadecadienoic acid, 13-oxo-cis-6,cis-9,cis-15-octadecatrienoic acid, 10,13-dioxo-octadecanoic acid, 10,13-dioxo-cis-6-octadecenoic acid, 10,13-dioxo-cis-15-octadecenoic acid, 10,13-dioxo-cis-6,cis-15-octadecadienoic acid, 13-oxo-cis-5,cis-9-octadecadienoic acid, or 13-oxo-trans-5,cis-9-octadecadienoic acid,
(3) the saturated fatty acid or the unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 9-position, the 14-position, the 17-position, which has 18 or 20 carbon atoms and a hydroxyl group or carbonyl group at the 12-position, is 12-hydroxy-octadecanoic acid, 12-hydroxy-cis-14-eicosenoic acid, 12-hydroxy-cis-14,cis-17-eicosadienoic acid, 12-hydroxy-cis-8,cis-14-eicosadienoic acid, 12-hydroxy-cis-5,cis-8-eicosadienoic acid, 12-hydroxy-cis-8,cis-14,cis-17-eicosatrienoic acid, 12-hydroxy-cis-5,cis-8,cis-14-eicosatrienoic acid, 12-oxo-octadecanoic acid, 12-oxo-cis-9-octadecenoic acid, 12-oxo-cis-14-eicosenoic acid, 12-oxo-cis-14,cis-17-eicosadienoic acid, 12-oxo-cis-8,cis-14-eicosadienoic acid, 12-oxo-cis-5,cis-8-eicosadienoic acid, 12-oxo-cis-8,cis-14,cis-17-eicosatrienoic acid, or 12-oxo-cis-5,cis-8,cis-14-eicosatrienoic acid,
(4) the unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 11-position, the 17-position, which has 20 carbon atoms and a hydroxyl group or carbonyl group at the 15-position, is 15-hydroxy-cis-11-eicosenoic acid, 15-hydroxy-cis-11,cis-17-eicosadienoic acid, 15-hydroxy-cis-8,cis-11-eicosadienoic acid, 15-hydroxy-cis-5,cis-8,cis-11-eicosatrienoic acid, 15-hydroxy-cis-8,cis-11,cis-17-eicosatrienoic acid, 15-hydroxy-cis-5,cis-11-eicosadienoic acid, 15-hydroxy-cis-5,cis-11,cis-17-eicosatrienoic acid, 15-oxo-cis-11-eicosenoic acid, 15-oxo-cis-11,cis-17-eicosadienoic acid, 15-oxo-cis-8,cis-11-eicosadienoic acid, 15-oxo-cis-5,cis-8,cis-11-eicosatrienoic acid, 15-oxo-cis-8,cis-11,cis-17-eicosatrienoic acid, 15-oxo-cis-5,cis-11-eicosadienoic acid, or 15-oxo-cis-5,cis-11,cis-17-eicosatrienoic acid, or
(5) the saturated fatty acid having 16 carbon atoms and a hydroxyl group or carbonyl group at the 10-position is 10-hydroxy-hexadecanoic acid or 10-oxo-hexadecanoic acid.

### Claim 6 (depends on 4)

The method according to claim 4, wherein
(1) the saturated fatty acid or the unsaturated fatty acid having a trans double bond at the 11-position or at least one cis double bond at the 6-position, the 12-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position, is 10-hydroxy-cis-12-octadecenoic acid, 10-hydroxy-octadecanoic acid, 10-oxo-cis-12-octadecenoic acid, 10-hydroxy-cis-12,cis-15-octadecadienoic acid, 10-hydroxy-cis-6,cis-12-octadecadienoic acid, 10-oxo-cis-12,cis-15-octadecadienoic acid, 10-oxo-cis-6,cis-12-octadecadienoic acid, 10-oxo-trans-11-octadecenoic acid, 10-oxo-trans-11,cis-15-octadecadienoic acid, or 10-oxo-cis-6,trans-11-octadecadienoic acid,
(2) the saturated fatty acid or the unsaturated fatty acid having at least one cis double bond at the 6-position, the 9-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position, is 13-hydroxy-cis-9-octadecenoic acid, 13-hydroxy-cis-6,cis-9-octadecadienoic acid, 13-hydroxy-cis-9,cis-15-octadecadienoic acid, 10,13-dihydroxy-octadecanoic acid, 10,13-dihydroxy-cis-6-octadecenoic acid, 10,13-dihydroxy-cis-15-octadecenoic acid, 13-oxo-cis-9-octadecenoic acid, 13-oxo-cis-6,cis-9-octadecadienoic acid, or 13-oxo-cis-9,cis-15-octadecadienoic acid, or
(3) the saturated fatty acid having 18 carbon atoms and a hydroxyl group at the 12-position is 12-hydroxy-octadecanoic acid.

### Claim 7 (depends on 3)

The method according to claim 3, wherein the inflammatory disease is an inflammatory disease involving macrophage.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the inflammatory disease is an inflammatory disease involving macrophage.

### Claim 9 (depends on 5)

The method according to claim 5, wherein the inflammatory disease is an inflammatory disease involving macrophage.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the inflammatory disease is an inflammatory disease involving macrophage.

### Claim 11

A method for inhibiting M1 macrophage, comprising administering to a patient an effective amount of a fatty acid that is
(1) a fatty acid having 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position,
(2) a fatty acid having 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position,
(3) a fatty acid having 18 or 20 carbon atoms and a hydroxyl group or carbonyl group at the 12-position,
(4) a fatty acid having 20 carbon atoms and a hydroxyl group or carbonyl group at the 15-position, or
(5) a fatty acid having 16 carbon atoms and a hydroxyl group or carbonyl group at the 10-position.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the fatty acid is
(1) a saturated fatty acid or an unsaturated fatty acid having a trans double bond at the 11-position or at least one cis double bond at the 6-position, the 12-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position,
(2) a saturated fatty acid or an unsaturated fatty acid having at least one cis double bond at the 6-position, the 9-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position,
(3) a saturated fatty acid or an unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 9-position, the 14-position, the 17-position, which has 18 or 20 carbon atoms and a hydroxyl group or carbonyl group at the 12-position,
(4) an unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 11-position, the 17-position, which has 20 carbon atoms and a hydroxyl group or carbonyl group at the 15-position, or
(5) a saturated fatty acid having 16 carbon atoms and a hydroxyl group or carbonyl group at the 10-position.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the fatty acid is
(1) a saturated fatty acid or an unsaturated fatty acid having a trans double bond at the 11-position or at least one cis double bond at the 6-position, the 12-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position, or
(2) a saturated fatty acid or an unsaturated fatty acid having at least one cis double bond at the 6-position, the 9-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position, or (3) a saturated fatty acid having 18 carbon atoms and a hydroxyl group at the 12-position.

### Claim 14 (depends on 12)

The method according to claim 12, wherein
(1) the saturated fatty acid or the unsaturated fatty acid having a trans double bond at the 11-position or at least one cis double bond at the 6-position, the 12-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position, is 10-hydroxy-cis-12-octadecenoic acid, 10-hydroxy-cis-12,cis-15-octadecadienoic acid, 10-hydroxy-cis-6,cis-12-octadecadienoic acid, 10-hydroxy-cis-6,cis-12,cis-15-octadecatrienoic acid, 10,12-dihydroxy-octadecanoic acid, 10-hydroxy-octadecanoic acid, 10-hydroxy-cis-15-octadecenoic acid, 10-hydroxy-cis-6-octadecenoic acid, 10-hydroxy-cis-6,cis-15-octadecadienoic acid, 10-hydroxy-trans-11-octadecenoic acid, 10-hydroxy-trans-11,cis-15-octadecadienoic acid, 10-hydroxy-cis-6,trans-11-octadecadienoic acid, 10-hydroxy-cis-6,trans-11,cis-15-octadecatrienoic acid, 10-oxo-cis-12-octadecenoic acid, 10-oxo-cis-12,cis-15-octadecadienoic acid, 10-oxo-cis-6,cis-12-octadecadienoic acid, 10-oxo-cis-6,cis-12,cis-15-octadecatrienoic acid, 10-oxo-octadecanoic acid, 10-oxo-cis-6-octadecenoic acid, 10-oxo-cis-15-octadecenoic acid, 10-oxo-cis-6,cis-15-octadecadienoic acid, 10-oxo-trans-11-octadecenoic acid, 10-oxo-cis-6,trans-11-octadecadienoic acid, 10-oxo-trans-11,cis-15-octadecadienoic acid, or 10-oxo-cis-6,trans-11,cis-15-octadecatrienoic acid,
(2) the saturated fatty acid or the unsaturated fatty acid having at least one cis double bond at the 6-position, the 9-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position, is 13-hydroxy-cis-9-octadecenoic acid, 13-hydroxy-cis-6,cis-9-octadecadienoic acid, 13-hydroxy-cis-9,cis-15-octadecadienoic acid, 13-hydroxy-cis-6,cis-9,cis-15-octadecatrienoic acid, 10,13-dihydroxy-octadecanoic acid, 10,13-dihydroxy-cis-6-octadecenoic acid, 10,13-dihydroxy-cis-15-octadecenoic acid, 10,13-dihydroxy-cis-6,cis-15-octadecadienoic acid, 10-oxo-13-hydroxy-octadecanoic acid, 10-oxo-13-hydroxy-cis-6-octadecenoic acid, 10-oxo-13-hydroxy-cis-15-octadecenoic acid, 10-oxo-13-hydroxy-cis-6,cis-15-octadecadienoic acid, 13-hydroxy-cis-5,cis-9-octadecadienoic acid, 13-hydroxy-trans-5,cis-9-octadecadienoic acid, 13-oxo-cis-9-octadecenoic acid, 13-oxo-cis-6,cis-9-octadecadienoic acid, 13-oxo-cis-9, cis-15-octadecadienoic acid, 13-oxo-cis-6,cis-9,cis-15-octadecatrienoic acid, 10,13-dioxo-octadecanoic acid, 10,13-dioxo-cis-6-octadecenoic acid, 10,13-dioxo-cis-15-octadecenoic acid, 10,13-dioxo-cis-6,cis-15-octadecadienoic acid, 13-oxo-cis-5,cis-9-octadecadienoic acid, or 13-oxo-trans-5,cis-9-octadecadienoic acid,
(3) the saturated fatty acid or the unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 9-position, the 14-position, the 17-position, which has 18 or 20 carbon atoms and a hydroxyl group or carbonyl group at the 12-position, is 12-hydroxy-octadecanoic acid, 12-hydroxy-cis-14-eicosenoic acid, 12-hydroxy-cis-14,cis-17-eicosadienoic acid, 12-hydroxy-cis-8,cis-14-eicosadienoic acid, 12-hydroxy-cis-5,cis-8-eicosadienoic acid, 12-hydroxy-cis-8,cis-14,cis-17-eicosatrienoic acid, 12-hydroxy-cis-5,cis-8,cis-14-eicosatrienoic acid, 12-oxo-octadecanoic acid, 12-oxo-cis-9-octadecenoic acid, 12-oxo-cis-14-eicosenoic acid, 12-oxo-cis-14,cis-17-eicosadienoic acid, 12-oxo-cis-8,cis-14-eicosadienoic acid, 12-oxo-cis-5,cis-8-eicosadienoic acid, 12-oxo-cis-8,cis-14,cis-17-eicosatrienoic acid, or 12-oxo-cis-5,cis-8,cis-14-eicosatrienoic acid,
(4) the unsaturated fatty acid having at least one cis double bond at the 5-position, the 8-position, the 11-position, the 17-position, which has 20 carbon atoms and a hydroxyl group or carbonyl group at the 15-position, is 15-hydroxy-cis-11-eicosenoic acid, 15-hydroxy-cis-11,cis-17-eicosadienoic acid, 15-hydroxy-cis-8,cis-11-eicosadienoic acid, 15-hydroxy-cis-5,cis-8,cis-11-eicosatrienoic acid, 15-hydroxy-cis-8,cis-11,cis-17-eicosatrienoic acid, 15-hydroxy-cis-5,cis-11-eicosadienoic acid, 15-hydroxy-cis-5,cis-11,cis-17-eicosatrienoic acid, 15-oxo-cis-11-eicosenoic acid, 15-oxo-cis-11,cis-17-eicosadienoic acid, 15-oxo-cis-8,cis-11-eicosadienoic acid, 15-oxo-cis-5,cis-8,cis-11-eicosatrienoic acid, 15-oxo-cis-8,cis-11,cis-17-eicosatrienoic acid, 15-oxo-cis-5,cis-11-eicosadienoic acid, or 15-oxo-cis-5,cis-11,cis-17-eicosatrienoic acid, or
(5) the saturated fatty acid having 16 carbon atoms and a hydroxyl group or carbonyl group at the 10-position is 10-hydroxy-hexadecanoic acid or 10-oxo-hexadecanoic acid.

### Claim 15 (depends on 13)

The method according to claim 13, wherein
(1) the saturated fatty acid or the unsaturated fatty acid having a trans double bond at the 11-position or at least one cis double bond at the 6-position, the 12-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 10-position, is 10-hydroxy-cis-12-octadecenoic acid, 10-hydroxy-octadecanoic acid, 10-oxo-cis-12-octadecenoic acid, 10-hydroxy-cis-12,cis-15-octadecadienoic acid, 10-hydroxy-cis-6,cis-12-octadecadienoic acid, 10-oxo-cis-12,cis-15-octadecadienoic acid, 10-oxo-cis-6,cis-12-octadecadienoic acid, 10-oxo-trans-11-octadecenoic acid, 10-oxo-trans-11,cis-15-octadecadienoic acid, or 10-oxo-cis-6,trans-11-octadecadienoic acid,
(2) the saturated fatty acid or the unsaturated fatty acid having at least one cis double bond at the 6-position, the 9-position, the 15-position, which has 18 carbon atoms and a hydroxyl group or carbonyl group at the 13-position, is 13-hydroxy-cis-9-octadecenoic acid, 13-hydroxy-cis-6,cis-9-octadecadienoic acid, 13-hydroxy-cis-9,cis-15-octadecadienoic acid, 10,13-dihydroxy-octadecanoic acid, 10,13-dihydroxy-cis-6-octadecenoic acid, 10,13-dihydroxy-cis-15-octadecenoic acid, 13-oxo-cis-9-octadecenoic acid, 13-oxo-cis-6, cis-9-octadecadienoic acid, or 13-oxo-cis-9,cis-15-octadecadienoic acid, or
(3) the saturated fatty acid having 18 carbon atoms and a hydroxyl group at the 12-position is 12-hydroxy-octadecanoic acid.
